Download PDF
Fortschr Neurol Psychiatr 2007; 75(12): 714-719
DOI: 10.1055/s-2006-944296
Originalarbeit
© Georg Thieme Verlag Stuttgart · New York

Pharmakologische Behandlungsansätze bei der frontotemporalen Demenz

Pharmacological Treatment Options in Frontotemporal DementiaH.  Kessler1 , T.  Supprian2 , P.  Falkai1
  • 1Klinik für Psychiatrie und Psychotherapie, Universitätsklinikum des Saarlandes (Direktor: Prof. Dr. P. Falkai)
  • 2Rheinische Kliniken Düsseldorf, Abteilung Gerontopsychiatrie (Abteilungsarzt: Priv.-Doz. Dr. T. Supprian)
Further Information

Publication History

Publication Date:
14 September 2006 (online)

    Permissions and Reprints

Zusammenfassung

Im Gegensatz zur Alzheimer-Demenz gibt es zur Pharmakotherapie frontotemporaler Demenzen (FTD) bislang kaum systematische Untersuchungen. Neurochemisch wird bei der FTD ein ausgeprägtes serotonerges Defizit angenommen. Dieses bildet die Grundlage für die Behandlung, insbesondere von Verhaltensstörungen, mit serotonergen Antidepressiva. Bislang sind jedoch nur Paroxetin und Trazodon in Studien der Evidenzklassen I und II untersucht. Die Ergebnisse zu Paroxetin sind uneinheitlich, und bei Trazodon ist ein relativ hohes Nebenwirkungsprofil zu berücksichtigen. Von den Substanzen mit primär antidementivem Ansatzpunkt gibt es bislang lediglich Klasse II-Evidenz für den Einsatz von Rivastigmin auch bei der FTD, wenngleich neurochemisch kein klarer Hinweis auf ein cholinerges Defizit bei dieser Demenzform vorliegt. Zu Memantine gibt es bislang keine publizierten Daten aus kontrollierten Studien für einen Einsatz bei der FTD.

Abstract

In contrast to Alzheimer's disease, there are only few systematic trials for drug therapy of frontotemporal dementia (FTD). Neurochemically, a strong serotonergic deficit is supposed in FTD. This is the rationale for treatment, especially of behavioral abnormalities, with serotonergic antidepressants. However, only paroxetine and trazodone have been studied in trials with class I and II evidence so far. The results of paroxetine are inconsistent; and for trazodone a number of potential side-effects must be considered. Moreover, there is class II evidence for rivastigmine in FTD, even though a cholinergic deficit in this type of dementia is questionable. There are no published data from controlled trials for the use of memantine in FTD so far.

Schlüsselwörter

frontotemperale Demenz - Pharmakotherapie - Trazodon - Paroxetin - Rivastigmin

Key words

frontotemporal dementia - pharmacotherapy - trazodone - paroxetine - rivastigmine

Literatur

  • 1 Sparks D L, Markesbery W R. Altered serotonergic and cholinergic synaptic markers in Pick's disease.  Arch Neurol. 1991;  48 796-799
    PubMedGoogle Scholar
  • 2 Procter A W, Qurne M, Francis P T. Neurochemical features of frontotemporal dementia.  Dement Geriatr Cogn Disord. 1999;  10 (suppl. 1) 80-84
    CrossrefPubMedGoogle Scholar
  • 3 Sjogren M, Minthon L, Passant U, Blennow K, Wallin A. Decreased monoamine metabolites in frontotemporal dementia and Alzheimer's disease.  Neurobiol Aging. 1998;  19 379-384
    CrossrefPubMedGoogle Scholar
  • 4 Mann J J. Role of the serotonergic system in the pathogenesis of major depression and suicidal behavior.  Neuropsychopharmacology. 1999;  21 99S-105S
    PubMedGoogle Scholar
  • 5 Anderson I M, Scott K, Harborne G. Serotonin and depression in frontal lobe dementia.  Am J Psychiatry. 1995;  152 645
    PubMedGoogle Scholar
  • 6 Swartz J R, Miller B L, Lesser I M, Darby A L. Frontotemporal dementia: Treatment response to serotonin selective reuptake inhibitors.  J Clin Psychiatry. 1997;  58 212-216
    CrossrefPubMedGoogle Scholar
  • 7 Moretti R, Torre P, Antonello R M, Cazzato G, Bava A. Frontotemporal dementia: Paroxetine as a possibile treatment of behavior symptoms. A randomized, controlled, open 14-month study.  Eur Neurol. 2003;  49 13-19
    CrossrefPubMedGoogle Scholar
  • 8 Cummings J L, Mega M, Gray K. et al . The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia.  Neurology. 1994;  44 2308-2314
    CrossrefPubMedGoogle Scholar
  • 9 Reisberg B, Borenstein J, Salob S P. et al . Behavioral symptoms in Alzheimer's disease: Phenomenology and treatment.  J Clin Psychiatry. 1987;  48 (suppl 1) 9-15
    PubMedGoogle Scholar
  • 10 Folstein M, Folstein S, McHugh P. Mini-Mental State. A practical method for grading the cognitive state of patients for the clinican.  J Psychiatr Res. 1975;  12 189-198
    CrossrefPubMedGoogle Scholar
  • 11 Manos P J. The utility of the ten-point clock test as a screen for cognitive impairment in general hospital patients.  Gen Hosp Psychiatry. 1997;  8 469-476
    PubMedGoogle Scholar
  • 12 Gorham D R. The Proverb Test. Missoula: Psychological Test Specialists 1956
    Google Scholar
  • 13 Stroop J R. Studies of interference in serial verbal reactions.  J Exp Psychol. 1935;  18 643-662
    CrossrefPubMedGoogle Scholar
  • 14 Greene J G, Smith R, Gardiner M, Timburg G C. Measuring behavioural disturbance of elderly demented patients in the community and its effects on relatives: A factor analytic study.  Age Ageing. 1982;  11 121-126
    PubMedGoogle Scholar
  • 15 Deakin J B, Rahmann S, Nestor P J, Hodges J R, Sahakian B J. Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial.  Psychopharmacology. 2004;  172 400-408
    CrossrefPubMedGoogle Scholar
  • 16 Lebert F, Pasquier F, Petit H. Trazodone in the treatment of behavior in frontotemporal dementia.  Hum Psychopharmacol Clin Exp. 1999;  14 279-281
    CrossrefPubMedGoogle Scholar
  • 17 Lebert F, Stekke W, Hasenbroekx C, Pasquier F. Frontotemporal dementia: A randomized, controlled trial with trazodone.  Dement Geriatr Cogn Disord. 2004;  17 355-359
    CrossrefPubMedGoogle Scholar
  • 18 Mattis S. Mental status examination for organic mental syndrome in the elderly patients. In: Bellak L, Karasu TB (eds). Geriatric Psychiatry. New York: Grune & Stratton 1986: 77-121
    Google Scholar
  • 19 Teri L, Logsdon R G, Peskind E. et al . Treatment of agitation in AD: A randomized, placebo-controlled clinical trial.  Neurology. 2000;  55 1271-1278
    PubMedGoogle Scholar
  • 20 Benkert O, Hippius H. Kompendium der Psychiatrischen Pharmakotherapie. Heidelberg: Springer 5. Aufl 2005: 96
    Google Scholar
  • 21 Adler G, Teufel M, Drach L M. Pharmacological treatment of frontotemporal dementia: treatment response to the MAO-A inhibitor moclobemide.  Int J Geriatr Psychiatry. 2003;  18 653-655
    CrossrefPubMedGoogle Scholar
  • 22 Chow T W. Treatment approaches to symptoms associated with frontotemporal degeneration.  Curr Psychiatry Rep. 2005;  7 376-380
    PubMedGoogle Scholar
  • 23 Thomas T. Monoamine oxidase-B inhibitors in the treatment of Alzheimer's Disease.  Neurobiol Aging. 2000;  21 343-348
    CrossrefPubMedGoogle Scholar
  • 24 Gerlach M, Riederer P, Youdim M BH. The molecular pharmacology of L-deprenyl.  Eur J Pharmacol. 1992;  226 97-108
    PubMedGoogle Scholar
  • 25 Moretti R, Torre P, Antonello R M, Cazzato G, Bava A. Effects of selegiline on fronto-temporal dementia: a neuropsychological evaluation.  Int J Geriatr Psychiatry. 2002;  17 391-392
    CrossrefPubMedGoogle Scholar
  • 26 Miller B L. Pick's Disease and Frontotemporal Dementias: Clinical and Biological Overview. Philadelphia: American Academy of Neurology 2001
    Google Scholar
  • 27 Lindau M, Almkvist O, Kushi J, Boone K, Johansson S E, Wahlund L O, Cummings J L, Miller B L. First symptoms - frontotemporal dementia versus Alzheimer's disease.  Dement Geriatr Cogn Disord. 2000;  11 286-293
    CrossrefPubMedGoogle Scholar
  • 28 Urrutia L, Read M, Swartz R, Miller B L. Differentiation of Alzheimer's disease, frontotemporal dementia, and parkinsonian dementias. In: Vellas BJ (ed). Alzheimer's disease, Facts and Research in Gerontology. Paris: Serdi 1996: 7-16
    Google Scholar
  • 29 Moretti R, Torre P, Antonello R M, Cattaruzza T, Cazzato G, Bava A. Rivastigmine in frontotemporal dementia. An open-label study.  Drugs Aging. 2004;  21 931-937
    CrossrefPubMedGoogle Scholar
  • 30 Sahakian B J, Coull J J, Hodges J R. Selective enhancement of executive function by idazoxan in a patient with dementia of the frontal lobe type.  J Neurol Neurosurg Psychiatry. 1994;  57 120-121
    PubMedGoogle Scholar
  • 31 Ross E D, Stewart R M. Akinetic mutism from hypothalamic damage: successful treatment with dopamine agonists.  Neurology. 1981;  31 1435-1439
    PubMedGoogle Scholar
  • 32 Imamura T, Takanashi M, Hattori N, Fujimori M, Yamashita H, Ishii K, Yamadori A. Bromocriptine treatment for perseveration in demented patients.  Alzheimer Dis Assoc Disord. 1998;  12 109-113
    PubMedGoogle Scholar
  • 33 Gold M, Van Dam D, Silliman E R. An open-label trial of bromocriptine in nonfluent aphasia: a qualitative analysis of word storage and retrieval.  Brain Lang. 2000;  74 141-156
    CrossrefPubMedGoogle Scholar
  • 34 Reed D A, Johnson N A, Thompson C, Weintraub S, Mesulam M M. A clinical trial of bromocriptine for treatment of primary progressive aphasia.  Ann Neurol. 2004;  56 750
    PubMedGoogle Scholar
  • 35 O'Suilleabhain P, Dewey Jr R B. A randomized trial of amantadine in Huntington disease.  Arch Neurol. 2003;  60 996-998
    CrossrefPubMedGoogle Scholar
  • 36 Verhagen Metman L, Morris M J, Farmer C, Gillespie M, Mosby K, Wuu J, Chase T N. Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine.  Neurology. 2002;  10 694-699
    PubMedGoogle Scholar
  • 37 Van Reekum R, Bayley M, Garner S, Burke I M, Fawcett S, Hart A, Thompson W. N of 1 study: amantadine for the amotivational syndrome in a patient with traumatic brain injury.  Brain Inj. 1995;  9 49-53
    PubMedGoogle Scholar
  • 38 Drayton S J, Davies K, Steinberg M, Leroi I, Rosenblatt A, Lyketsos C G. Amantadine for executive dysfunction syndrome in patients with dementia.  Psychosomatics. 2004;  45 205-209
    CrossrefPubMedGoogle Scholar
  • 39 Chow T W. Frontotemporal dementia: clinical diagnosis and management.  Semin Clin Neuropsychiatry. 2003;  8 58-70
    CrossrefPubMedGoogle Scholar
  • 40 Chow T W, Mendez M F. Goals in symptomatic pharmacologic management of frontotemporal lobar degeneration.  Am J Alzheimer's Dis Other Dement. 2002;  17 267-272
    PubMedGoogle Scholar
  • 41 Talerico K A, Evans L K. Responding to safety issues in fronto-temporal dementias.  Neurology. 2001;  56 (suppl. 4) S52-S55
    PubMedGoogle Scholar
  • 42 Greck J, Lautenschlager N, Kurz A. Klinische Aspekte der frontotemporalen Demenz.  Fortschr Neurol Psychiat. 2000;  68 447-457
    Article in Thieme ConnectPubMedGoogle Scholar
  • 43 Iyer M B, Mattu U, Grafman J, Lomarev M, Sato S, Wassermann E M. Safety and cognitive effect of frontal DC brain polarization in healthy individuals.  Neurology. 2005;  64 872-875
    CrossrefPubMedGoogle Scholar

Dr. med. Holger Kessler

Klinik für Psychiatrie und Psychotherapie Universitätsklinikum des Saarlandes

66421 Homburg/Saar

Email: holger.kessler@uniklinik-saarland.de

      >